Trial Profile
Prospective study of Imetelstat in patients with essential thrombocytopenia (ET)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2015
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary)
- Indications Essential thrombocythaemia
- Focus Pharmacogenomic; Therapeutic Use
- 10 Nov 2015 New trial record
- 05 Nov 2015 According to a Geron Corporation media release, results from this study will be presented at the 57th American Society of Hematology Annual meeting.